ReviewFrontiers in oncology2022
Glioblastoma Microenvironment: From an Inviolable Defense to a Therapeutic Chance.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 26 citations in OpenAlex.
- First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax).Frontiers in immunology · 2024Trial
- Enhancer of Zeste Homolog 2 (EZH2): From Glioblastoma Biology to Potential Epigenetic Therapy.International journal of molecular sciences · 2026Review
- Review
- Reprogramming the immunosuppressive microenvironment in glioblastoma: the microglia-MDSC-Treg axis and translational therapeutic strategies.Frontiers in oncology · 2026Review
- Dimensional memory in glioblastoma mechanics: Traction force analysis of cells cultured in 2D versus 3D collagen environments.Bioactive materials · 2026Article
- The dynamic myeloid-enriched microenvironment of glioblastoma: a major challenge to immunotherapy efficacy.Frontiers in immunology · 2026Review
- Clinical and genetic determinants of glioblastoma survival: a retrospective study.Frontiers in molecular neuroscience · 2026Article
- 3D Brain Vascular Niche Model Captures Glioblastoma Infiltration, Dormancy, and Gene Signatures.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Glycosylation Gene Signatures as Prognostic Biomarkers in Glioblastoma.Annals of clinical and translational neurology · 2025Article
- Kinin BPharmaceuticals (Basel, Switzerland) · 2025Article
- Article
- Recapitulating Glioma Stem Cell Niches Using 3D Spheroid Models for Glioblastoma Research.Biosensors · 2024Review
- Neuroinflammation in Glioblastoma: Progress and Perspectives.Brain sciences · 2024Review
- Results from a first-in-human phase I safety trial to evaluate the use of a vascularized pericranial/temporoparietal fascial flap to line the resection cavity following resection of newly diagnosed glioblastoma.Journal of neuro-oncology · 2024Article
- Glioblastoma: An Update in Pathology, Molecular Mechanisms and Biomarkers.International journal of molecular sciences · 2024Review
- Glioblastoma Therapy: Past, Present and Future.International journal of molecular sciences · 2024Review
- Review
- Identification of Breast Cancer Subtypes by Integrating Genomic Analysis with the Immune Microenvironment.ACS omega · 2023Article
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma is an aggressive tumor and is associated with a dismal prognosis. The availability of few active treatments as well as the inexorable recurrence after surgery are important hallmarks of the disease. The biological behavior of glioblastoma tumor cells reveals a very complex pattern of genomic alterations and is partially responsible for the clinical aggressiveness of this tumor. It has been observed that glioblastoma cells can recruit, manipulate and use other cells including neurons, glial cells, immune cells, and endothelial/stromal cells. The final result of this process is a very tangled net of interactions promoting glioblastoma growth and progression. Nonetheless, recent data are suggesting that the microenvironment can also be a niche in which glioblastoma cells can differentiate into glial cells losing their tumoral phenotype. Here we summarize the known interactions between micro-environment and glioblastoma cells highlighting possible therapeutic implications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.